The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial‐like head and neck carcinoma subtypes

Pavón, Miguel Ángel; Arroyo‐Solera, Irene; León, Xavier; Gabriel, Marta Tellez; Virós, David; Gallardo, Alberto; Céspedes, María Virtudes; Casanova, Isolda; Pousa, Antonio López; Barnadas, Agustí; Quer, Miquel; Mangues, Ramón

doi:10.1002/hed.25623

Cited by 11 publications

(9 citation statements)

References 79 publications

(169 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After adjusting for confounding factors, it was demonstrated that the expression of SPRR1A was an independent predictor for OS. In accordance with previous findings (10,11), these results revealed the prognostic implication of SPRR1A in colon cancer. A tendency was indicated between high SPRR1A expression and the incidence of distant metastasis (high expression vs. low expression, 15.9% vs. 3%); however, no significant differences were indicated.…”

Section: Discussionsupporting

confidence: 93%

“…Relapse-free and disease-free survival indicated no tumor recurrence in patients. such as diffuse large B-cell lymphomas (9), head and neck squamous cell carcinoma (10) and breast (12) cancer. Leclerc et al (12) reported high expression of SPRR1A in a murine preneoplastic intestine and in the normal intestinal mucosa of patients with CRC.…”

Section: Discussionmentioning

confidence: 99%

“…Previously, it has been described as a specific marker of differentiation of keratinocytes and squamous epithelial cells (6,8). Accumulating evidence has revealed the prognostic importance of the high expression of SPRR1A in various types of cancer, including diffuse large B-cell lymphomas (9), head and neck squamous cell carcinoma (10), and breast cancer (11). In addition, high SPRR1A expression was also reported in a murine preneoplastic intestine and in the normal intestinal mucosa of patients with colorectal cancer (CRC) (12).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

High SPRR1A expression is associated with poor survival in patients with colon cancer

et al. 2020

View full text Add to dashboard Cite

High expression of small proline-rich protein 1A (SPRR1A) has been shown to be associated with tumor prognosis; however, the association between SPRR1A expression and colon cancer prognosis remains unclear. The present study sought to evaluate the association between SPRR1A expression and the clinicopathological characteristics of colon cancer, and to examine its potential prognostic value. A total of 114 patients with colon cancer were included. SPRR1A expression was evaluated by immunohistochemical staining, and the association between SPRR1A expression and clinicopathological parameters was analyzed. The prognostic value of SPRR1A was analyzed by Cox regression analysis, the Oncomine database and the R2 platform. SPRR1A expression was significantly increased in cancerous tissues compared with that in adjacent non-cancerous tissues. SPPRR1A expression was significantly associated with lymph node invasion. High SPRR1A expression was significantly associated with worse overall and disease-free survival rate. Cox regression analysis revealed that T stage, pathological N stage and high SPRR1A expression remained independent predictors for overall survival rate. The Oncomine database analysis demonstrated that SPRR1A mRNA expression levels were significantly increased in colorectal cancer tissues compared with those in adjacent non-cancerous tissues, and high SPRR1A expression was associated with a significantly worse event-and relapse-free survival time in the R2 platform. The data indicate that SPRR1A may serve as a potential biomarker for the prognosis of colon cancer.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High SPRR1A expression is associated with poor survival in patients with colon cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The SPRR genes encode a class of polypeptides (small proline rich proteins) that are involved in differentiation of keratinocytes, the primary cell type of the epidermis. SPRR1A is known to play a role in various types of cancer, such as diffuse large B-cell lymphomas [ 39 ], head and neck squamous cell carcinoma [ 40 ], and breast cancer [ 41 ]. The overexpression of SPRR1B has been shown to enhance the entry of cells in the G0 phase of the cell cycle [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT

Patil

Linge

Hiepe

et al. 2022

Cancers

View full text Add to dashboard Cite

(1) Background: Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who are biologically at high risk for the development of loco–regional recurrences after postoperative radiotherapy (PORT) but at intermediate risk according to clinical risk factors may benefit from additional concurrent chemotherapy. In this matched-pair study, we aimed to identify a corresponding predictive gene signature. (2) Methods: Gene expression analysis was performed on a multicenter retrospective cohort of 221 patients that were treated with postoperative radiochemotherapy (PORT-C) and 283 patients who were treated with PORT alone. Propensity score analysis was used to identify matched patient pairs from both cohorts. From differential gene expression analysis and Cox regression, a predictive gene signature was identified. (3) Results: 108 matched patient pairs were selected. We identified a 2-metagene signature that stratified patients into risk groups in both cohorts. The comparison of the high-risk patients between the two types of treatment showed higher loco–regional control (LRC) after treatment with PORT-C (p < 0.001), which was confirmed by a significant interaction term in Cox regression (p = 0.027), i.e., the 2-metagene signature was indicative for the type of treatment. (4) Conclusion: We have identified a novel gene signature that may be helpful to identify patients with high-risk HNSCC amongst those at intermediate clinical risk treated with PORT, who may benefit from additional concurrent chemotherapy.

show abstract

“…(C and D) Tumor volumes were measured every five days and calculated as described in the Method section, which revealed that SPRR2B-shRNA significantly attenuated tumor growth while overexpressing SPRR2B exerted opposite effects. malignancy progression, such as SPRR1A, [25][26][27][28] SPRR1B, [29][30][31] SPRR2A, [32][33][34][35] and SPRR3. [36][37][38][39] However, SPRRs can serve as either tumor suppressors 39 or oncoproteins 38 in different malignancies.…”

Section: Discussionmentioning

confidence: 99%

Small Proline-Rich Protein 2B Facilitates Gastric Adenocarcinoma Proliferation via MDM2-p53/p21 Signaling Pathway

Yao¹,

Yan²,

Cheng³

et al. 2021

OTT

View full text Add to dashboard Cite

Background The small proline-rich protein 2B (SPRR2B) was firstly reported as a member of the cross-linked envelope protein in keratinocytes. The effect of SPRR2B in gastric adenocarcinoma (GC) remains unclear. This study initially explored the clinical significance of SPRR2B in GC patients as well as its role in tumor progression. Methods Immunohistochemistry was performed to characterize the expression of SPRR2B in GC tissues and adjacent tissues. The relationship between SPRR2B expression and clinicopathological features of GC patients was analyzed by Chi-square test. Kaplan-Meier method and Cox regression analyses were utilized to identify the prognostic factors of GC. Overexpression and knockdown assays were conducted to investigate possible signaling pathways downstream of SPRR2B. Flow cytometry assays were performed to evaluate cell cycle and apoptosis. Xenograft experiments were performed to validate tumor-related role of SPRR2B in vivo. Results Both mRNA and protein levels of SPRR2B in cancerous tissue were significantly higher than those in non-cancerous tissues. Meanwhile, SPRR2B expression was significantly associated with tumor size and tumor stage. Survival analysis revealed SPRR2B as one of the independent prognosis factors for overall survival of GC patients. Cellular and xenografts data implicated that silencing SPRR2B blocked the cell cycle of GC cells perhaps through MDM2-p53/p21-CDK1 pathway, while overexpressing SPRR2B exhibited opposite effects. Conclusion Our data suggest that SPRR2B may serve as a novel prognostic marker in GC, which functions at least partially by MDM2-p53/p21-CDK1 signaling pathway.

show abstract

The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial‐like head and neck carcinoma subtypes

Cited by 11 publications

References 79 publications

High SPRR1A expression is associated with poor survival in patients with colon cancer

High SPRR1A expression is associated with poor survival in patients with colon cancer

A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT

Small Proline-Rich Protein 2B Facilitates Gastric Adenocarcinoma Proliferation via MDM2-p53/p21 Signaling Pathway

Contact Info

Product

Resources

About